FDA accepted Rhythm's supplemental New Drug Application, and Morgan Stanley reiterated a Buy rating, while the European Medicines Agency is reviewing the drug.
2 reports, 2 independent
Updated Aug 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted Rhythm's supplemental New Drug Application, and Morgan Stanley reiterated a Buy rating, while the European Medicines Agency is reviewing the drug.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA accepted Rhythm's SNDA, while Morgan Stanley reiterated a Buy rating and EMA reviews the drug.1 source
Rhythm reached commercial stage as a biopharmaceutical firm on August 7, 2025.1 source
Keep exploring
The entities involved
- FDA
-
Rhythm (United states)
company in Boston, United States
Nothing else this week.
Related events
- The FDA is currently reviewing new drug applications for market entry.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- Both the FDA and the European Medicines Agency govern drug approval processes.
Coverage
Newest first; wire copies grouped- Insider MonkeyFDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM) Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 20
- Simply Wall St.Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term Explore Rhythm Pharmaceuticals's Fair Values from the Community and select yours Rhythm Pharmaceuticals